Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Included Health filed to go public for a 2022 IPO that never happened. Now, it's private, profitable, and bigger than before.
Included Health filed its S-1 for an IPO that never happened. Its CEO said the company went heads-down to reach profitability and sales growth.
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...
Titan America Sets IPO Terms That Could Push Market Cap Above $3 Billion
Titan America, which makes heavy building materials and operates primarily on the U.S. Eastern Seaboard, on Tuesday said it plans to sell 9 million shares at between $15 and $18 apiece in the IPO, for ...
Karman Holdings Aims High With $100 Million US IPO Plan
Learn about Karman Holdings' upcoming $100 million US IPO, their focus on missile and space systems, and the financial ...
LNG Exporter Venture Global Raises $1.75 Billion in US IPO
Venture Global is the second-largest exporter of liquefied natural gas, or LNG, in the United States, and one of Trump's ...
J&J-Backed Medtech Firm HistoSonics Considers US IPO
HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...
Titan America Announces Launch of Initial Public Offering
Titan America SA ("Titan America"), a subsidiary of Titan Cement International SA and parent company of its U.S. operations, ...